Test Price
2,800 AED✅ Home Collection Available
ERF Gene Craniosynostosis Type 4 Genetic Test in UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Core Metrics at a Glance
Test Overview & Methodology
The ERF Gene Craniosynostosis Type 4 Genetic Test is a clinically validated, single-gene sequencing assay that screens the entire coding region of the ERF (ETS2 Repressor Factor) gene for pathogenic variants linked to autosomal dominant craniosynostosis type 4 — a disorder characterized by premature fusion of cranial sutures, craniofacial dysmorphology, and potential neurodevelopmental implications. This test is indicated for pediatric patients presenting with abnormal head shape, syndromic facies, or a family history of craniosynostosis, and is processed at our DHA-licensed molecular diagnostics facility (License: 1143).
| Feature | Our ERF NGS Test | Closest Alternative (Panel-Based) |
|---|---|---|
| Methodology | NGS — Full Gene Sequencing (Single-Gene Focus) | Multi-Gene Panel (NGS) — Broader but Diluted Depth |
| Diagnostic Precision | 99.9% Analytical Sensitivity for ERF Coding Variants | ~98% — Dependent on Panel Coverage Uniformity |
| Turnaround Time | 3 to 4 Weeks | 4 to 8 Weeks (Larger Batches) |
| Sample Types | Whole Blood · Extracted DNA · Dried Blood Spot (FTA Card) | Whole Blood or Extracted DNA Only |
| Genetic Counselling | Included — Pre- & Post-Test Pedigree & Clinical Correlation | Often Optional or Fee-Based |
Physician Insight & Safety Protocols
"As a Consultant Medical Geneticist specializing in craniofacial disorders, I strongly advise that a positive ERF variant result must always be interpreted within the full clinical context — genotype alone does not dictate phenotype. This test offers critical molecular confirmation, but families require a comprehensive craniofacial evaluation, neurodevelopmental monitoring, and individualized surgical planning when indicated. A negative result, equally, does not exclude the diagnosis if clinical suspicion remains high; expert clinical correlation is mandatory."
— Dr. Lina Osama Zaki Quteineh, DHA Registration ID: 9294403, Consultant Medical Genetics
⚠️ Clinical Advisory: Do not discontinue any prescribed medication or alter your child's treatment plan based on genetic test results alone. Genetic findings must be integrated into the broader clinical picture by your managing physician and do not independently override ongoing therapeutic protocols.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do Not Proceed If:
- Patient has received a blood transfusion within the last 14 days (risk of donor DNA contamination).
- Active severe infection with hemodynamic instability — phlebotomy deferred until clinical stabilization.
- Inability to obtain informed consent from a legal guardian (mandatory for minors under UAE Federal Law).
- Unlabeled or improperly sealed DNA/Blood specimen — rejected per ISO 9001:2015 chain-of-custody protocol.
Emergency Red Flags — Seek Immediate Medical Attention:
- Signs of raised intracranial pressure: projectile vomiting, sunsetting eyes, bulging fontanelle, or rapid head circumference increase.
- New-onset seizures or altered consciousness in a child with known or suspected craniosynostosis.
- Apneic episodes, bradycardia, or stridor in an infant — potential brainstem compression.
If any emergency red flag symptom is present, proceed directly to the nearest emergency department. Do not wait for genetic test results.
Patient FAQ & Clinical Guidance
1. How accurate is the ERF Gene NGS test in confirming craniosynostosis type 4?
A: This NGS-based ERF gene test achieves 99.9% analytical sensitivity and specificity for detecting single nucleotide variants, small insertions, deletions, and splice-site mutations within the full coding region of the ERF gene. Clinical correlation by a board-certified geneticist remains essential, as variant pathogenicity classification follows ACMG/AMP guidelines and may require familial segregation studies for variants of uncertain significance (VUS).
2. What sample types are accepted and how is home collection arranged?
A: We accept Whole Blood (3–5 mL in EDTA tube), Extracted DNA (minimum 1 µg at ≥50 ng/µL), or a single drop of blood on an FTA Card — making pediatric collection minimally invasive. Our ISO-certified VIP mobile phlebotomy team serves all seven Emirates from 8 AM to 11 PM daily — simply WhatsApp +971 54 548 8731 to schedule a home visit, and our cold-chain logistics ensure sample integrity from your doorstep to our DHA-licensed laboratory.
3. Does UAE insurance cover the ERF craniosynostosis genetic test?
A: Many UAE insurance providers cover single-gene NGS testing for craniosynostosis when justified by a referring pediatrician, clinical geneticist, or neonatologist citing ICD-10-CM diagnostic codes and documented clinical necessity. We provide direct billing verification — send your insurance card and Emirates ID via WhatsApp to +971 54 548 8731, and our patient liaison team will confirm coverage eligibility within 2 business hours, in full compliance with UAE PDPL data privacy regulations.
UAE Regulatory & Data Privacy Adherence
Your Genomic Data is Protected by Law
DNA Labs UAE operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient genomic data is encrypted, stored locally within UAE sovereign infrastructure, and never shared with unauthorized third parties. Our DHA license (No. 1143) mandates strict adherence to these frameworks. Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring every procedure is ethically and legally sound.
Our ISO 9001:2015 Certified Quality Management System (Cert: INT/EGQ/2509DA/3139) guarantees that all testing workflows meet international standards for molecular diagnostics.
Clinical & Logistical Metadata
| Test Name | ERF Gene Craniosynostosis Type 4 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coding Region Analysis |
| ICD-10-CM Code | Q75.0, Q87.0, Z13.71 |
| LOINC Code | 81247-7 |
| DHA Facility License & Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians